Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

illion and $37.4 million for the corresponding periods in 2006. The 2007 increase primarily resulted from higher sales and marketing expenses associated with the expansion of ISTA's sales force in early 2007. Stock-based compensation expenses included in SG&A for the fourth quarter and for the year ended December 31, 2007 were $0.8 million and $2.5 million, respectively.

The net loss for the fourth quarter and year ended December 31, 2007, was $9.9 million (or $0.30 per share) and $38.2 million (or $1.29 per share), respectively, compared with a net loss of $6.4 million (or $0.25 per share) and $38.4 million (or $1.48 per share) for the same periods in 2006. At December 31, 2007, ISTA had cash and short-term investments of $46.1 million.

2007 Corporate Highlights

-- Increased net revenue by 56% and 78% as compared to the fourth quarter

of 2006, and year ended December 31, 2006, respectively

-- Filed an NDA with the FDA for Xibrom QD (once-daily) in December of

2007 after announcing, earlier in the year, positive Phase III results

for Xibrom QD as a treatment for inflammation, pain, and photophobia

following cataract surgery

-- Announced statistically significant Phase II/III study results for

Bepreve in treating ocular itching and clinical improvement in redness

and initiated both the Bepreve ocular safety study and the second

Phase III study

-- Announced positive results from the ecabet sodium Phase IIb study for

the treatment of dry eye syndrome

-- Successfully completed $36.7 million financing through the private

placement of 5.25 million shares of common stock with institutional

accredited investors at a purchase price of $7.00 per share

-- Expanded pipeline in allergy treatments by licensing exclusive North

American rights to nasal dosage forms of bepotastine, an

investigation
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 2014 An analysis by Replikins, Ltd. of ... Mers CoV virus strains has revealed extensive conservation ... This conservation and sharing of specific Replikin gene structures ... candidate, as it did for the H5N1 influenza vaccine ... have been found to be effective (1,2). ...
(Date:8/26/2014)... , August 26, 2014 , ... hospitals with surgery validation using its Stratasys Objet24 and Objet30 ... surgery on 3D printed models prior to operations reduces theatre ... effective aid for both patient and surgeon   ... a global leader of 3D printing and additive manufacturing solutions, ...
(Date:8/26/2014)... AVENTURA. Fla. , Aug. 26, 2014 /PRNewswire/ ... trades under the symbol (NUUU) has two (2) ... Inc. Our two subsidiaries harness scientifically advanced technology ... NUUU,s Renuell Int,l, Inc. ... breakthrough anti-aging skin care products that is made ...
(Date:8/26/2014)... , Aug. 26, 2014 Trovagene, Inc. ... Generation Dx Summit; Moving Assays to the Clinic ... and Monitoring of Cell Free Tumor DNA in ... component of its Precision Cancer Monitoring (PCM) platform ... sensitivity for the detection of tumor DNA mutations ...
Breaking Biology Technology:Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4
... TELK ) announced that its 2008 second quarter ... 11, 2008 at 4:30 p.m. Eastern time,(1:30 p.m. Pacific ... financial results for the second quarter ended June 30, ... Telik,s website at, http://www.telik.com or by telephone at ...
... Aug. 4 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... Bio-Tech Products (Shandong) Co., Ltd. (Kiwa Shandong),has ... China Organic Food,Certification Center (COFCC)., After ... appraisal of,Kiwa Shandong,s products, the China Organic ...
... Share Proposal is Best and Final Offer, INDIANAPOLIS, ... ) today reaffirmed that its $3.00 per share purchase ... its best and final offer,for the San Diego-based biotechnology ... signing of a definitive merger agreement, whereby,Lilly will acquire ...
Cached Biology Technology:Kiwa Bio-Tech Receives Nationally Recognized Organic Products Certification 2Kiwa Bio-Tech Receives Nationally Recognized Organic Products Certification 3Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 3
(Date:8/26/2014)... increased risk of autism among children of women ... the known increased risk associated with severe maternal ... publication in Molecular Psychiatry , investigators from ... a diagnosis of autism spectrum disorder was more ... during pregnancy than in those with no prenatal ...
(Date:8/25/2014)... has experienced widespread adoption of robot-assisted prostate removal ... The BJU International study also found ... traditional surgeries, their costs are decreasing over time. ... in operations to remove the prostate. To examine ... prostatectomy (RARP) procedures for prostate cancer patients, Steven ...
(Date:8/25/2014)... Diego School of Medicine have found one of the ... a deadly brain cancer are resistant to drug therapy. ... tumor, but in its epigenetic signature. These findings have been ... Oncotarget . , "There is a growing interest to ... cell," said Clark Chen, MD, PhD, vice-chairman of Research and ...
Breaking Biology News(10 mins):Study calls into question link between prenatal antidepressant exposure and autism risk 2Study calls into question link between prenatal antidepressant exposure and autism risk 3US has seen widespread adoption of robot-assisted cancer surgery to remove the prostate 2Finding keys to glioblastoma therapeutic resistance 2
... at the Texas A&M Health Science Center Institute ... Edinburgh have uncovered how a bacterial pathogen interacts ... methicillin-resistant Staphylococcus aureus (MRSA) infections, a ... the potentially deadly disease. Their work appears ...
... the wrong times, the results can be genetic disaster. ... in fruit flies that yank chromosomes, the DNA-carrying structures, ... condensin II, separate chromosomes by twisting them into supercoils ... Scientists had known of condensin II but did ...
... ON A new and insidious environmental threat ... researchers from Queen,s and York universities. Along ... team has documented biological damage caused by declining ... Calling the phenomenon "aquatic osteoporosis," Queen,s PhD ...
Cached Biology News:Keeping chromosomes from cuddling up 2Keeping chromosomes from cuddling up 3Queen's University biologists find new environmental threat in North American lakes 2
Acetylcholinesterase from human and monkey....
...
... Dye runs faster than Bromophenol blue,or ... gels.,Orange G dye migrates with DNA ... migration at this size,prevents the obscuring ... the front of DNA migration.,The Orange ...
... Gel loading solution, ... for non-denaturing polyacrylamide and ... nucleic acids and offers ... tracking dyes (bromphenol blue ...
Biology Products: